Kardigan was able to upsize its IPO, raising more cash for three drug candidates in mid-stage clinical development for cardiovascular conditions with no available therapies. All three programs are expected to report key data in 2027 that could pave the way for Phase 3 testing. The post Kardigan’s IPO Lands $400M for Drugs That Get…
A recent JAMA editorial from two radiologists argues that elective whole-body MRI scan companies are misleading consumers about the benefits of said scans. The radiologists argue the MRIs are more likely to trigger harmful downstream procedures than they are to save lives. Not surprisingly, the three most prominent companies offering these scans denied the charge….
These structures, if not set up and managed correctly from day one, can create significant accounting, tax and compliance headaches down the road. The post What Life Sciences Companies Get Wrong When Building Cross-Border R&D Structures appeared first on MedCity News.
The future of healthcare depends on enterprises moving decisively beyond the pilot trap by treating enterprise AI as a platform capable of sustaining hundreds of dynamic models. The post Beyond the Pilot Trap: How Healthcare Can Scale AI Without Losing Trust appeared first on MedCity News.
AI documentation tools are genuinely useful. But they are treating a symptom, not the disease. The disease is that physicians have lost control over how they work. The post AI Won’t Fix Physician Burnout — Giving Them More Autonomy Will appeared first on MedCity News.
AI hasn’t solved all the problems plaguing healthcare’s revenue cycle — but R1’s Lee Kupferman says that it is getting closer, one gray area at a time. The post What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle? appeared first on MedCity News.
KFF’s analysis found that the average number of issuers offering plans on the Marketplaces declined to 9 issuers per state in 2026, compared to 9.6 issuers per state in 2025. The post KFF: Insurer Participation in ACA Marketplaces Is Down appeared first on MedCity News.
UniQure is preparing to seek accelerated FDA approval for its Huntington’s disease gene therapy, a move that follows the FDA’s reversal of its prior position calling for another clinical trial. This gene therapy is the latest in a growing list of rare disease treatments to receive reconsideration from an FDA that appears to be swinging…
Combined upper and lower GI endoscopy is becoming standard practice across many US healthcare settings, but the quality infrastructure for upper GI has not kept pace with the procedures now being performed on it. The post Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards appeared…
The healthcare organizations getting this right are not defined by how much they’ve automated. They are defined by how deliberately they’ve protected the human touchpoints that drive trust, engagement, and outcomes. The post The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate appeared first on MedCity News.